SymBio Pharmaceuticals Limited
SYMQY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $8,680,612 | $9,561,313 | $26,363,248 | $10,803,198 |
| - Cash | $3,963,580 | $6,517,007 | $6,282,554 | $3,860,106 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4,717,032 | $3,044,306 | $20,080,694 | $6,943,092 |
| Revenue | $2,452,912 | $5,589,708 | $10,008,338 | $8,252,582 |
| % Growth | -56.1% | -44.1% | 21.3% | – |
| Gross Profit | $1,873,189 | $4,411,014 | $7,599,904 | $5,800,111 |
| % Margin | 76.4% | 78.9% | 75.9% | 70.3% |
| EBITDA | -$3,778,972 | -$715,663 | $2,061,718 | $1,109,960 |
| % Margin | -154.1% | -12.8% | 20.6% | 13.4% |
| Net Income | -$3,833,480 | -$1,962,817 | $1,179,238 | $2,032,203 |
| % Margin | -156.3% | -35.1% | 11.8% | 24.6% |
| EPS Diluted | -84.06 | -49.19 | 29.77 | 52.32 |
| % Growth | -70.9% | -265.2% | -43.1% | – |
| Operating Cash Flow | -$3,416,518 | -$194,685 | $1,614,241 | $140,042 |
| Capital Expenditures | -$46,877 | -$232,797 | -$47,558 | -$63,837 |
| Free Cash Flow | -$3,463,395 | -$427,482 | $1,566,683 | $76,205 |